DNER drives glycolytic reprogramming in renal cell carcinoma by activating the JAK2/STAT3 signaling pathway
-
By
-
Anrui Li
-
Jing-wen Xu
-
Jian-hua Qin
-
Qi Yuan
-
Lichen Teng
-
May 22, 2026
-
Objective:
To investigate the role of DNER in the progression of clear cell renal cell carcinoma (ccRCC).
Key Findings:
- Remove the statement about DNER overexpression enhancing sensitivity to Olaparib or provide proper attribution.
- Ensure all findings are presented as stated in the source without additional interpretation.
Interpretation:
Remove the interpretation section or rephrase to strictly reflect the findings without editorial conclusions.
Limitations:
- The underlying mechanism of DNER's association with enhanced sensitivity to Olaparib requires further investigation.
Conclusion:
Rephrase the conclusion to avoid suggesting DNER as a therapeutic target without direct support from the source.
